Aurora Cannabis Past Earnings Performance
Past criteria checks 3/6
Aurora Cannabis has been growing earnings at an average annual rate of 13.4%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 1.9% per year. Aurora Cannabis's return on equity is 71.5%, and it has net margins of 148.9%.
Key information
13.4%
Earnings growth rate
26.4%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 1.9% |
| Return on equity | 71.5% |
| Net Margin | 148.9% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Aurora launches new cannabis products for adult and medical-use
Oct 17Aurora Cannabis further strengthens its balance sheet by repurchasing ~US$23M of convertible notes
Oct 07Aurora Cannabis Q4 2022 Earnings Preview
Sep 19Aurora Cannabis: Don't Let Your Money Go Up In Smoke
Aug 25Why Did Aurora Cannabis Stock Crash In May; Can It Recover?
Jun 13Recent Developments Do Not Change Our Stance On Aurora Cannabis
May 13Aurora Cannabis: A Train Wreck Desperate For Help
May 05Aurora Cannabis: The Fallen Pot Giant That Still Can't Find Its Way
Feb 17Aurora Cannabis Vs. HEXO: Which Is The Better Cannabis Stock?
Dec 17Tilray Vs. Aurora Cannabis: How To Compare These Cannabis Stocks
Oct 11Aurora Cannabis: Investors Should Have No Confidence In This Company
Sep 28Is Aurora Cannabis Stock A Buy Or Sell Before Upcoming Earnings? Buy The U.S. Opportunity
Sep 16Aurora Cannabis Is A Pass For Now, Although We Are Bullish On The Industry
Jun 05Aurora Cannabis: Extreme Downside Case Averted
Feb 02Aurora Cannabis inks exclusive representative agreement with Great North Distributors
Jan 14How To Recoup Your Losses In Aurora Cannabis
Dec 24Aurora downgraded by BMO citing ‘out-of-line’ valuation
Dec 18Aurora to lay off 200 employees, idles substantial part of flagship Sky marijuana facility
Dec 16It's Not Just Aurora, Bearish On All Cannabis Stocks
Dec 08U.S. House gears up for historic vote on cannabis legalization
Dec 04Aurora Cannabis (ACB) Investor Presentation - Slideshow
Dec 02Aurora Cannabis inks supply deal for bulk dried flower with Cantek, shares down 6%
Nov 25Pot stocks rally as Trump administration proceeds with transition to Biden
Nov 24Revenue & Expenses BreakdownBeta
How Aurora Cannabis makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 276 | 411 | 126 | 5 |
| 30 Sep 23 | 273 | 374 | 125 | 6 |
| 30 Jun 23 | 258 | 331 | 127 | 6 |
| 31 Mar 23 | 233 | -265 | 135 | 7 |
| 31 Dec 22 | 212 | -1,748 | 163 | 8 |
| 30 Sep 22 | 210 | -1,757 | 180 | 8 |
| 30 Jun 22 | 221 | -1,718 | 176 | 10 |
| 31 Mar 22 | 226 | -1,233 | 185 | 11 |
| 31 Dec 21 | 231 | -381 | 189 | 12 |
| 30 Sep 21 | 238 | -607 | 188 | 13 |
| 30 Jun 21 | 245 | -692 | 195 | 11 |
| 31 Mar 21 | 257 | -2,387 | 206 | 16 |
| 31 Dec 20 | 275 | -2,359 | 241 | 18 |
| 30 Sep 20 | 263 | -3,342 | 300 | 23 |
| 30 Jun 20 | 269 | -3,231 | 346 | 26 |
| 31 Mar 20 | 299 | -1,405 | 372 | 24 |
| 31 Dec 19 | 291 | -1,430 | 397 | 22 |
| 30 Sep 19 | 290 | -385 | 376 | 17 |
| 30 Jun 19 | 246 | -294 | 365 | 15 |
| 31 Mar 19 | 168 | -211 | 327 | 10 |
| 31 Dec 18 | 119 | -72 | 253 | 7 |
| 30 Sep 18 | 77 | 174 | 187 | 5 |
| 30 Jun 18 | 55 | 72 | 110 | 2 |
| 31 Mar 18 | 42 | -13 | 69 | 1 |
| 31 Dec 17 | 31 | 7 | 45 | 0 |
| 30 Sep 17 | 23 | -4 | 31 | 0 |
| 30 Jun 17 | 18 | -13 | 25 | 0 |
| 31 Mar 17 | 13 | -16 | 19 | 0 |
| 31 Dec 16 | 8 | -13 | 13 | 0 |
| 30 Sep 16 | 5 | -10 | 8 | 1 |
| 30 Jun 16 | 1 | -6 | 6 | 1 |
| 31 Mar 16 | 0 | 0 | 5 | 1 |
| 31 Dec 15 | 0 | -3 | 4 | 1 |
| 30 Sep 15 | 0 | -10 | 4 | 1 |
| 30 Jun 15 | 0 | -10 | 4 | 0 |
Quality Earnings: ACB has a high level of non-cash earnings.
Growing Profit Margin: ACB became profitable in the past.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: ACB has become profitable over the past 5 years, growing earnings by 13.4% per year.
Accelerating Growth: ACB has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.
Earnings vs Industry: ACB has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-0.5%).
Return on Equity
High ROE: ACB's Return on Equity (71.5%) is considered outstanding.